Cel Injectable bulking agents have been attempted to treat and manage stress urinary incontinence since the 1990's. But their application has been limited by efficacy, durability, biocompatibility, usability and other issues. Lack of a single, reproducible response from one agent has led to the adoption of several such materials. However, none of those materials can be used as a scaffold for tissue regeneration, they are mostly temporary tissue fillers. Once they degrade, the effectivity is diminished, typically within 6-8 months only. A permanent bulking agent was not successful as it often causes immunological adverse events (such as foreign body granulomas) that limit safety and efficacy. Between 1995-2011 a bovine crosslinked collagen product – Contigen® was used successfully to treat PMSI in dogs, however its production was stopped in 2011. CellFoam™ is a biomaterial scaffold augmentation agent that stimulates the body own cells to build de-novo tissue in place of the biomaterial. Thus, when degraded, a long-term tissue augmentation effect is maintained by urethral remodelling. As such continence is resolved. The overarching objective of the present feasibility study is to mitigate risks related to subsequent phases of the CellFoam™ innovation project, i.e. the risks associated with the planned industrialization, the commercialization of the solution and post-project exploitation of the results. Dziedzina nauki medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsagricultural sciencesanimal and dairy sciencedomestic animalsmedical and health sciencesmedical biotechnologytissue engineeringsocial sciencespolitical sciencespolitical transitionsrevolutionsengineering and technologyindustrial biotechnologybiomaterials Program(-y) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Temat(-y) SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2016-2017 System finansowania SME-1 - SME instrument phase 1 Koordynator BIO-CHANGE LTD Wkład UE netto € 50 000,00 Adres KIBUTZ NAHSHOLIM 30815 KIBUTZ NAHSHOLIM Izrael Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00